| Similar Articles |
|---|
 |
The Motley Fool
April 18, 2011
Jeremy Phillips |
Time to Sell Force Protection? Today I'm laser-focused on Force Protection, ready to evaluate its price, valuation, margins, and liquidity. Let's get started!   |
The Motley Fool
October 9, 2010
Jeremy Phillips |
Should You Sell Best Buy Right Now? Best Buy has failed four of these quick tests that would make it a sell. |
The Motley Fool
October 16, 2010
Jeremy Phillips |
Time to Sell Progress Energy? Let's focus on Progress Energy and evaluate its price, valuation, margins, and liquidity to search for danger signs. |
The Motley Fool
August 10, 2006
Stephen D. Simpson |
Volatility, Thy Name Is Hospira Margins continue to stand in the way of consistent performance at the health-care company. Investors, take note. |
The Motley Fool
November 9, 2006
Brian Lawler |
Hospira's Flatlining Sales There's no good news to be found in this medical products supplier's medicine chest. The upcoming fourth quarter isn't going to be any better, either. Investors, take note. |
The Motley Fool
May 9, 2006
Stephen D. Simpson |
Riding the Hospira Yo-Yo There's a solid foundation on this roller coaster pharmaceutical and drug delivery company. Maybe Hospira's current valuation doesn't make it a "gem," but that's not really within its control. |
The Motley Fool
June 2, 2005
Brian Gorman |
Hospira's Little Purchase There may be more to Hospira's recent acquisition than meets the eye. |
The Motley Fool
November 10, 2005
Stephen D. Simpson |
Hospitable Treatment for Hospira Solid margins fuel strong earnings at the hybrid generics - medical distributor. Buying this stock wisely may be the key to good long-term returns. |
The Motley Fool
July 8, 2010
Selena Maranjian |
Get 2-for-1 Stock-Price Growth This one-two punch can lead to serious gains. Stocks that offer both earnings growth and P/E growth can help you rack up knockout returns over the long haul. |
The Motley Fool
August 8, 2007
Ryan Fuhrmann |
Hospira Looks to Deliver Will a recent acquisition boost drug delivery firm Hospira's growth prospects? The new Mayne Pharma Limited division played a primary role in delivering an impressive 30% reported sales growth. |
BusinessWeek
May 31, 2004
Robert Barker |
Hospira Just May Put You In The Pink If the Abbott Laboratories spin-off's first steps hardly seem promising, that's one reason why I see the company as worth much more of the intelligent investor's attention than the long calendar of pending tech and biotech IPOs. |
The Motley Fool
December 15, 2010
Seth Jayson |
Does This Mean Hospira Will Burn You? Investors should watch Hospira's top line carefully during the next quarter or two. |
The Motley Fool
May 13, 2005
Brian Gorman |
Hospira's Hopeful Signs The medical products company's strong quarter belies a less exciting future. Investors should probably take a wait-and-see attitude. |
The Motley Fool
March 1, 2007
Brian Lawler |
Hospira's Boring Growth The medical products provider announces its fourth quarter financial results and gives guidance for 2007. Investors, take note. |
The Motley Fool
October 28, 2010
Anand Chokkavelu |
7 Health-Care Stocks Near 52-Week Highs Searching the market's peaks for possibilities. |
The Motley Fool
March 1, 2006
Brian Gorman |
Hospira's Stumble In spite of an unsightly quarter, good things still are happening at this medical products and services outfit. Investors, take note. |
The Motley Fool
July 19, 2005
Stephen D. Simpson |
Peek-a-Boo ICU ICU Medical has taken on quite a bit of risk in the process of remaking the company. It's best to wait for a reasonable valuation before buying shares. |
The Motley Fool
November 11, 2004
Brian Gorman |
Hospira's Possibilities The medical products and services outfit is not flashy, but it may benefit from long-term trends. Their stock may be worth monitoring. |
The Motley Fool
September 10, 2010
Eben Esterhuizen |
10 Stocks in Rally Mode That Seem Undervalued Despite strong performance of late, these stocks are still cheaper than their competitors. |
The Motley Fool
September 22, 2006
Brian Lawler |
Hospira's New Mate Down Under The specialty injectable pharmaceutical announces an acquisition, but the move means adding on a lot more debt. Investors, take note. |
The Motley Fool
August 8, 2011
Seth Jayson |
Why the Street Should Expect Big Things from Hospira Although Hospira shows inventory growth that outpaces revenue growth, the company may also display positive inventory divergence, suggesting that management sees increased demand on the horizon. |
Pharmaceutical Executive
September 1, 2012
Bill Trombetta |
Pharm Exec's 11th Annual Industry Audit: Busting the Tape With pharmaceuticals are eyed as a commodity purchase, those traditional high margins are getting harder to find. Shareholder value and profits now depends on finding pockets of "good" growth, in segments with long-term potential in serving an unmet medical need, with fewer players. |
The Motley Fool
August 5, 2010
Seth Jayson |
Show Me the Money, Alcon With questionable cash sources comprising 4% of the cash flow from operations for Alcon, I am pretty confident things are OK. |
Chemistry World
February 12, 2015
Rebecca Trager |
Hospira buyout is a shot in the arm for Pfizer's biosimilars Pfizer said in a statement that its acquisition of Hospira will create 'a leading global sterile injectables business. |
The Motley Fool
January 31, 2006
Stephen D. Simpson |
Guidance Puts ICU Medical in the Trauma Ward This oft-volatile stock had a strong fourth quarter, but weak guidance. Even with today's steep drop in price, the shares aren't cheap enough to be interesting. |
The Motley Fool
February 23, 2004
Brian Gorman |
Abbott Cleans Up Its Act Abbott closes the books on its problems with the FDA and clears the way to a spinoff. Abbott finally passed FDA muster with its Illinois diagnostics plant. Its multi-year problem highlights the importance of investors monitoring manufacturing while watching a pharmaceutical company's pipeline. And with its FDA compliance issues behind it, Abbott can look forward to spinning off its Hospital Products Division. |
IndustryWeek
June 1, 2007
Traci Purdum |
500 Largest U.S. Manufacturers: Manufacturing Giants This group of manufacturing leaders is demonstrating how to stay competitive in a global economy. |
